Effects of cotrimoxazole on hematologic parameters in HIV-infected adults in a community-based clinic in entebbe, Uganda [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 3, 2007, Pages 369-371

  Watera, Christine ^a   Todd, Jim ^a   Mutonyi, Gertrude ^a   Miiro, George ^a   Mpendo, Juliet ^a   Hughes, Peter ^a   Nakiyingi Miiro, Jessica ^a   Whitworth, Jimmy ^a   Grosskurth, Heiner ^a  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; FOLIC ACID ANTAGONIST; HEMOGLOBIN; ZIDOVUDINE;

ANEMIA; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; NEUTROPENIA; PARAMETERS OF MEASUREMENT AND ANALYSIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UGANDA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; BLOOD CELL COUNT; CD4 LYMPHOCYTE COUNT; HEMOGLOBINS; HIV INFECTIONS; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; PLATELET COUNT; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UGANDA;

EID: 37349097290     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181170c47     Document Type: Letter

References (9)

1. Watera C, Todd J, Muwonge R, et al. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. J Acquir Immune Defic Syndr. 2006;42:373-378.
2. Mermin J, Lule J, Ekwaru J, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428-1434.
3. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire. A randomised trial. Lancet. 1999;353:1463-1468.
4. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet. 1999;353:1469-1475.
5. World Health Organization/United Nations Program on HIV/AIDS. Provisional WHO/UNAIDS Secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. 2000. Available at: http://data.unaids.org/Publications/IRC-pub04/recommendation_en.pdf. Accessed April 16, 2007.
6. Toure S, Gabillard D, Inwoley A, et al. Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Cote d'Ivoire. Trans R Soc Trop Med Hyg. 2006;100:785-790.
7. Moh R, Danel C, Sorho S, et al. Haematological changes in adults receiving a zidovudine containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther. 2005;10:615-624.
8. Ssali F, Stohr W, Munderi P, et al. Prevalence, incidence and predictors of severe anemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther. 2006;11:741-749.
9. French N, Nakiyingi J, Carpenter LM, et al. 23-Valent pneumococcal polysaccharide vaccine in HV-1-infected Ugandan adults: double-blind, randomised and placebo-controlled trial. Lancet. 2000;355:2106-2111.